Atlas Trials

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT06465329 · RECRUITING

Trial details

NCT number
NCT06465329
Sponsor
Regeneron Pharmaceuticals
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2024-11-18
Primary completion
2027-05-20
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.